Investment to Create Pan-European CRO


French and Spanish CROs combine on expertise to address cross-country clinical trials.

Henko Partners, an Iberian private equity firm, has announced its investment in PopsiCube and MissionTEC, two French CROs. PopsiCube operates in various therapeutic areas including oncology, rare diseases, and cardiovascular disease, and its subsidiary MissionTEC has developed strategies needed for decentralized clinical trials.

Along with BioClever, a CRO in Spain with strong expertise in biometrics and a Henko Partners investment since July 2022, the equity firm is building a pan-European CRO that will offer an expanded range of clinical trials services cross-country, in addition to servicing national markets. The new European CRO will manage early to late phase studies and including decentralized clinical trials.

The founders and current management team of PopsiCube will continue to lead the company. Henko will provide operating support alongside capital to accelerate the business plan.

Reference: Henko Partners invests in PopsiCube and MissionTEC to create a European CRO. Madrid, May 4, 2023.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.